Question 65

Strattera is at risk of being confused with Atomoxetine.

Strattera, which is the brand name, has the generic name Atomoxetine, thus it is inherently at risk of being confused with its own generic name.

A) Atomoxetine

This option is correct because Atomoxetine is the generic name for Strattera. The potential for confusion arises because the brand and generic names are often used interchangeably, leading to errors in medication administration.

B) dapagliflozin

Dapagliflozin is a completely different medication used to treat type 2 diabetes. It is not related to Strattera or its generic name, Atomoxetine, and therefore does not pose any risk of confusion in this context.

C) rivaroxaban

Rivaroxaban is an anticoagulant medication used to prevent blood clots. There is no similarity in name or function with Strattera or Atomoxetine, making it an unlikely candidate for confusion.

D) famotidine

Famotidine is an antihistamine that reduces stomach acid production. Like the previous options, it has no connection to Strattera or Atomoxetine, and therefore does not present a risk of confusion.

Conclusion

The identification of Atomoxetine as the correct answer highlights the importance of recognizing the potential for name confusion in medications. While other options listed are distinct from Strattera and do not contribute to confusion, the relationship between Strattera and its generic name Atomoxetine underscores the critical need for clarity in medication naming conventions.